NCT00563147View on ClinicalTrials.gov

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

February 28, 2011

Conditions
Renal Cell Carcinoma
Interventions
DRUG

tivozanib (AV-951) plus temsirolimus

ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days

Trial Locations (5)

33612

H. Lee Moffitt Cancer Center, Tampa

68114

Nebraska Methodist Hospital, Omaha

77030

The Methodist Hospital Research Institute, Houston

90095

UCLA Jonsson Comprehensive Cancer Center, Los Angeles

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY